chronic prostatitis

Known as: PROSTATITIS, CHRONIC, prostatitis chronic 
An infectious or non-infectious chronic inflammatory process that affects the prostate gland.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Benign prostatic hyperplasia (BPH) is a common disorder affecting 50-80% of the aged male population. Androgens and age have been… (More)
  • figure 1
  • figure 2
Is this relevant?
2009
2009
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 1. Chronic Prostatitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 1.1 Category I: Acute Bacterial Prostatitis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 1.2 Cat gory II: Chronic Bacterial Prostatitis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 1.3 Category III: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) . . . . . . . . . . . . . . . . . . . 74 1.4 Category IV: Asymptomatic Inflammatory Prostatitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 1.5 Presentation of CP/CPPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 1.6 Epidemiology of CP/CPPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 1.7 Pathophysiology of CP/CPPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 1.8 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 2. Treatment of CP/CPPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78 2.1 Surgical Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78 2.2 Pelvic Floor Biofeedback . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78 2.3 Antimicrobials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78 2.4 a-Adrenergic Receptor Antagonists (a-Blockers). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 2.5 Combination Therapy with a-Blockers and Fluoroquinolones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 2.6 Anti-Inflammatory Agents. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80 2.7 5a-Reductase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80 2.8 Glycosaminoglycans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80 2.9 Phytotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 2.10 Others . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 2.11 Role of the Pharmacist . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 3. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 Abstract TheNational Institutes of Health (NIH) has redefined prostatitis into four distinct entities. Category I is acute bacterial prostatitis. It is an acute prostatic infection with a uropathogen, often with systemic symptoms of fever, chills and hypotension. The treatment hinges on antimicrobials and drainage of the bladder because the inflamed prostate may block urinary flow. Category II prostatitis is called chronic bacterial prostatitis. It is characterized by recurrent episodes of documented urinary tract infections with the same uropathogen and causes pelvic pain, urinary symptoms and ejaculatory pain. It is diagnosed by means of localization cultures that are 90% accurate in localizing the source of recurrent infections within the lower urinary tract. Asymptomatic inflammatory prostatitis comprises NIH category IV. This entity is, by definition, asymptomatic and is often diagnosed incidentally THERAPY IN PRACTICE Drugs 2009; 69 (1): 71-84 0012-6667/09/0001-0071/$55.55/0TheNational Institutes of Health (NIH) has redefined prostatitis into four distinct entities. Category I is acute bacterial prostatitis. It is an acute prostatic infection with a uropathogen, often with systemic symptoms of fever, chills and hypotension. The treatment hinges on antimicrobials and drainage of the bladder because the inflamed prostate may block urinary flow. Category II prostatitis is called chronic bacterial prostatitis. It is characterized by recurrent episodes of documented urinary tract infections with the same uropathogen and causes pelvic pain, urinary symptoms and ejaculatory pain. It is diagnosed by means of localization cultures that are 90% accurate in localizing the source of recurrent infections within the lower urinary tract. Asymptomatic inflammatory prostatitis comprises NIH category IV. This entity is, by definition, asymptomatic and is often diagnosed incidentally THERAPY IN PRACTICE Drugs 2009; 69 (1): 71-84 0012-6667/09/0001-0071/$55.55/0 a 2009 Adis Data Information BV. All rights reserved. 
  • table I
  • figure 1
  • figure 2
  • table II
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND In men with chronic prostatitis-chronic pelvic pain syndrome, treatment with alpha-adrenergic receptor blockers early… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
OBJECTIVE This prospective study quantified cytokine and chemokine levels in seminal plasma of patients with chronic prostatitis… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PURPOSE We describe the study design of the National Institutes of Health Chronic Prostatitis Cohort (CPC) study characterizing… (More)
Is this relevant?
2002
2002
A total of 388 patients with symptoms of chronic prostatitis and inflammatory findings in expressed prostatic secretion (EPS) or… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PURPOSE We examine whether leukocytes and bacteria correlate with symptom severity in men with chronic prostatitis/chronic pelvic… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
OBJECTIVES An association between prostatitis and male infertility has been suspected, yet is poorly understood. Prostatitis is… (More)
  • table I
Is this relevant?
Highly Cited
1999
Highly Cited
1999
OBJECTIVES The National Institutes of Health (NIH) category III chronic prostatitis syndromes (nonbacterial chronic prostatitis… (More)
  • table I
  • figure 1
Is this relevant?
Highly Cited
1996
Highly Cited
1996
PURPOSE There is evidence that many patients experiencing chronic idiopathic prostatitis or prostadynia not only have recurrent… (More)
Is this relevant?